Navigation Links
ANI Pharmaceuticals, Inc. Announces Date for Third Quarter 2013 Earnings Release
Date:10/29/2013

BAUDETTE, Minn., Oct. 29, 2013 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its third quarter 2013 earnings before the market opens on Thursday, November 7th, 2013.

About ANI

ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has twelve products in development. ANI's targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. ANI's other products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. For more information please visit our website www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of the merger, the combined company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in
'/>"/>

SOURCE ANI Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity
2. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum
3. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
4. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
5. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
6. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG
7. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
8. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
9. Harwood Feffer LLP Announces Investigation of Transcept Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. Raises $50 Million In Additional Financing
11. Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "New EU Pharmacovigilance Legislation (London, UK - ... The 15 new EU modules concerning Pharmacovigilance ... Pharmacovigilance is conducted in Europe . ... these modules and their requirements, examine how they overlap ...
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... 18 New data evaluating the impact of screening ... prostate cancer screening. The Prostate Conditions Education Council ... a leader in prostate cancer screening, announced today that ... from two studies, including the preliminary data from the ...
... Platform Designed for Radial Strength, FlexibilityHOUSTON, March 18 ... in the development and marketing of minimally invasive ... Drug Administration (FDA) has approved an investigational device ... its SUPERA stent, a novel stent platform designed ...
Cached Medicine Technology:Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 2Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 3U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2
(Date:9/3/2015)... ... September 03, 2015 , ... The ... Clinicians Report of Provo, Utah. The Clinicians Report is a leading information source ... dentists located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we ... with the traditional health care model, where the primary care physician dictates and the ... want to become educated about their health issues and empowered to choose their own ...
(Date:9/3/2015)... ... ... When looking at the types of people who have a hard time gaining weight ... a weak appetite or those that have a fast metabolism. In order to help those ... gives three tips for slowing down metabolism. , The first thing to do is to ...
(Date:9/3/2015)... Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases of ... One in seven men will be diagnosed with prostate cancer during their lifetime. While only ... to six of every 10 men by age 65, according to the American Cancer ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Local filmmakers and ... Hannah & Michael Habernig from Path 11 Productions have had great success in launching ... podcast has featured Hay House authors, Teal Swan who is the well known Spiritual ...
Breaking Medicine News(10 mins):Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3
... ... Fax Technology and New HTTPS Platform, , ... Tigard, OR and Salem, OR (PRWEB) September 23, 2009 -- ... FaxBack, a leading provider of reliable VoIP Fax solutions for SMB, enterprise and carrier ...
... Oakstone ... the American College of Physicians. Available in two versatile audio formats designed to allow physicians ... ... the first section of the MKSAP 15 Audio Companion . Available in compact disc ...
... ... medical device testing , ... OH (PRWEB) September 23, 2009 -- NAMSA,s Analytical Chemistry department is on the move. ... facility is now in use at NAMSA. , , , , ,The ...
... with negative sputum tests by a new method, according ... cause of death worldwide, and while the diagnosis of ... can be identified on sputum microscopy, in about half ... making another diagnostic option critical in efforts to control ...
... NEW YORK, Sept. 22 Preet Bharara, the U.S. Attorney for ... formerly the senior manager of human resources of Hitachi America Ltd. ... months in prison for defrauding the Hitachi America Group Health and ... was imposed by U.S. District Judge Colleen McMahon. Dowd pleaded guilty ...
... , The LFA asks people to join them and ... an FDA-approved medication specifically for lupus , , ... Drug Administration (FDA) approved a medication to treat lupus -- when Dwight ... and effective medications, the Lupus Foundation of America, Inc. (LFA) today launched ...
Cached Medicine News:Health News:Pangea Communications and FaxBack Extend Their Alliance to Streamline Least Cost Routing and Enhance the Reliability of VoIP-Fax 2Health News:Pangea Communications and FaxBack Extend Their Alliance to Streamline Least Cost Routing and Enhance the Reliability of VoIP-Fax 3Health News:Oakstone Produces Self-Assessment Audio Updates to Support the American College of Physicians' MKSAP 15 2Health News:NAMSA Unveils New, Larger State-of-the-Art Analytical Chemistry Facility 2Health News:New test quickly ID's active TB in smear-negative patients 2Health News:Former Corporate Benefits Manager Sentenced to 57 Months in Prison for Defrauding Health Care Plan of More Than $6 Million Dollars 2Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
Medicine Products: